Drug Update

The Food and Drug Administration (FDA) is continuously approving new drugs, and we want to ensure our Clients are aware of these new approvals and drugs as they enter the market. The table below includes the drugs that are most likely to impact your plan. The full list of recent approvals can be found below the chart.

 

Posted: Mar 20 2017

New FDA Approved Drugs

Each month the FDA approves new medications, and below is a highlight of the most relevant new approvals and/or drugs which have the potential to impact your prescription plan. While the medications below have been evaluated and approved by the FDA, they may not enter the marketplace for several weeks or months. Therefore, pricing information for these medications is typically unavailable at the time of approval.


New Brand Approvals
Drug NameUses/TreatmentsPricing InformationOther Information
Siliq (brodalumab)Treatment of moderate to server plaque psoriasis in adults who have failed or lost response to other systemic therapies.Pricing information not yet available.• Drug Information: Siliq is available as a 210 mg single-dose prefilled syringe injected subcutaneously every two weeks following initiation.
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to Max Dollar and Max Dose edits.
• BIC SpecialtyRx: Comprehensive clinical management and competitive discounts via MedTrak’s BIC Specialty Pharmacy Network. 
Emflaza (deflazacort)Treatment of Duchenne muscular dystrophy in patients 5 years of age and older.Dosing is weight-based and total costs will vary amongst patients.• Drug Information: Emflaza is the first steroid approved in the U.S. for specific use in the treatment of Duchenne muscular dystrophy (DMD).
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to Max Dollar and Max Dose edits.
• BIC SpecialtyRx: Comprehensive clinical management and competitive discounts via MedTrak’s BIC Specialty Pharmacy Network. 
Qtern (dapagliflozin/saxagliptin)Treatment of type 2 diabetes in adults as an adjunct to diet and exercise.Pricing information not yet available.• Drug Information: Qtern is a combination of previously approved Farxiga and Onglyza.
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to Max Dollar and Max Dose edits.
• Diabetes CareTrakRx:  Qtern will be assessed for potential inclusion and management within MedTrak’s Diabetes CareTrakRx program. 



Download Report as PDF
Search Drug Updates